ST Hulus: Subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. obtains the drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution

ST Huluwa announces that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution. This medication is used to treat chronic constipation and fecal impaction. The main active ingredients are polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate, developed by Norgine in the UK. The company has invested a total of RMB 762,100 in research and development. After obtaining the certificate, the product will further enrich the company’s product portfolio.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin